Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILYX-002 for dry-eye disease in adults with autoimmune disease
ACTRN12623001230640Phase 2Completed
- Sponsor
- Iolyx
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ILYX 002 in dry eye syndrome (DED) (4 arms), sponsored by Iolyx. Primary endpoints: Safety and tolerability of ILYX-002 versus vehicle and Change from baseline to Week 8 in total lissamine green conjunctival staining score. Started Oct 2023; status: completed.
02
Drugs
ILYX 002
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ACTRN12623001230640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001230640.